Affordable Access

Publisher Website

The role of hydroxyurea in the management of sickle cell disease

Authors
Journal
Blood Reviews
0268-960X
Publisher
Elsevier
Publication Date
Volume
17
Issue
2
Identifiers
DOI: 10.1016/s0268-960x(02)00074-7
Keywords
  • Sickle
  • Hydroxyurea
  • Crisis
  • Hbf
  • Toxicity
Disciplines
  • Medicine

Abstract

Abstract Sickle cell disease (SCD) is one of the most common genetic diseases with some 250,000 new births each year. Most patients suffer intermittent pain crises and life-threatening events while life expectancy is considerably reduced. Until the last decade management was purely preventative or supportive aimed at symptom control. Apart from stem cell transplant, there is no cure but the oral chemotherapeutic drug hydroxyurea (HU) has now established a role in ameliorating the disease and improving life expectancy for most patients. There are side effects and risks of HU treatment in SCD but for moderate and severely affected patients, the benefits can be significant.

There are no comments yet on this publication. Be the first to share your thoughts.